Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Actavis, Inc. (ACT - Analyst Report) recently said that the US District Court for the District of New Jersey has granted AstraZeneca’s (AZN - Analyst Report) motion to issue a temporary restraining order (TRO) preventing Actavis from selling its generic version of AstraZeneca's Pulmicort Respules.

The TRO comes a few days after the court had ruled that Actavis’ generic version of Pulmicort Respules (0.25, 0.5 and 1 mg) does not infringe US Patent No. 7,524,834. The court also held that US Patent No. 6,598,603 was invalid.

The TRO prevents Actavis from distributing its generic version of Pulmicort Respules (0.25 and 0.5 mg) until Apr 12, 2013 so as to provide AstraZeneca with the chance to seek injunctive relief in the Court of Appeals.

Our Take

The launch of a generic version of Pulmicort Repsules, which is approved for the controlling and prevention of asthma symptoms in children aged 12 months to 8 years, would be a major boost for Actavis. Total branded and generic sales of Pulmicort Repsules in the US were $1.2 billion during the 12 months ended Jan 31, 2013. Teva (TEVA - Analyst Report) currently markets the generic version of Pulmicort Respules under an agreement with AstraZeneca. The entry of additional generic competition in the market would also have an impact on Teva’s top and bottom line.

Actavis intends to provide updated guidance on May 2 when the company is slated to announce its first quarter 2013 earnings.

Actavis currently holds a Zacks Rank #3 (Hold). While AstraZeneca and Teva are also Zacks Rank #3 stocks, Mylan (MYL - Analyst Report) currently looks attractive with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%